For Pulmonary Hypertension Awareness Month, we asked Scleroderma Research Foundation (SRF) board member Bob Smith his thoughts on the need for additional therapies for treating scleroderma-associated pulmonary arterial hypertension (PAH).
“We have come a long way in developing novel therapies for treating these high-risk patients. In my work in the pharmaceutical industry, I’ve been focused for over a decade on bringing life-changing therapies to scleroderma patients with PAH,” he says. “Having seen friends afflicted with this disease, I think it is vital that we accelerate investment in research to improve quality of life and outcomes for people with scleroderma.”
Bob adds, “I am so proud of the work that SRF is doing for scleroderma patients, including the CONQUER Registry. SRF’s commitment to scleroderma research is unparalleled. This is why I’m on the Board of Directors at SRF—so that I can be part of a team that is truly dedicated to advancing the best research to solve problems like PAH for scleroderma patients.”
